MedTrace Logo

Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

NCT04854980 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2025-03-30

No results posted yet for this study

Summary

To explore the immune response to the COVID-19 vaccine in cancer patients and compare to the general population.

Conditions

Interventions

OTHER

Blood Sample

Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-03
Primary Completion
2022-03-15
Completion
2024-07-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04854980 on ClinicalTrials.gov